AQST News and Press, Aquestive Therapeutics Inc. From 12/21/21

Aquestive Therapeutics (NASDAQ:AQST) drops 32.8% premarket after receiving FDA notification regarding the review of the New Drug Application (NDA) for Libervant (diazepam) Buccal Film for the treatment of breakthrough seizures and seizure clusters. The notice stated, "the Agency is ...

WARREN, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that, regarding t...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Harmony Biosciences Holdings (NASDAQ:HRMY), Aquestive Therapeutics (NASDAQ:AQST), C4 Therapeutics (NASDAQ:CCCC), Century Therapeutics (NASDAQ:IPSC), COMPASS Pathways (NASDAQ:CMPS) have been added to the Nasdaq Biotechnology Index. All the additions will be effective prior to market ...

WARREN, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that NASDAQ...

Gainers: Spruce Biosciences (NASDAQ:SPRB) +30%. Coherus BioSciences (NASDAQ:CHRS) +11%. TPI Composites (NASDAQ:TPIC) +6%. Lyell Immunopharma (NASDAQ:LYEL) +4%. Aquestive Therapeutics (NASDAQ:AQST) +4%. Losers: Adagio Therapeutics (NASDAQ:ADGI) -5%. Leslie's (NASDAQ:LESL) -3%. Rivian Automotiv...

FDA confirms 505(b)(2) pathway is acceptable for the development of AQST-109 FDA indicates AQST-109 has the potential for Fast Track designation Health Canada provides clearance to commence the adaptive design crossover study WARREN, N.J., Dec. 13, 2021 (GLOB...

Aquestive Therapeutics is moving closer to Libervant’s PDUFA date in December. If approved, Aquestive will finish 2021 on a bullish note that can be sustained into 2022. Aquestive has fought through COVID-19 headwinds and was able to report a strong beat on Q3 with SYMPAZAN con...

JERSEY CITY, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for its nov...

WARREN, N.J., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the manageme...